CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Clinical Trials
Original article

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

ConferencepositiveSKB500Positive
AI Analysis

Summary

Kelun-Biotech presented first-in-human study data for SKB500, a novel B7-H3 antibody-drug conjugate, at the 2026 ASCO Annual Meeting in Chicago.

Clinical Trial Data

Phase

Phase_1

Outcome Details

First-in-human study data presented

Importance:5/10
Sentiment:
0.50
oncologyADCB7-H3first-in-humanASCO 2026China
Related Companies
$AHR$DFPH$SKBBY$CPHI$TRAX

Read the original article

Published by PR Newswire Clinical Trials on June 3, 2026 12:00 AM

Read Original